Neuromodulation for Behavioral Changes in Neurological Disorders

The purpose of this study is to see if a focused ultrasound neuromodulation can be safely and effectively used to treat symptoms of emotional dysregulation such as agitation, irritability and anxiety

* Age 45-80 years at time of enrollment. * Diagnosis of probable mild-stage neurodegenerative dementia, including Alzheimer's disease (AD), frontotemporal dementia (FTD, including behavioral variant and language variant), or dementia with Lewy bodies (LBD), based on established consensus clinical criteria. * Presence of clinically meaningful (in treatment for or recommended for the symptoms) neuropsychiatric or behavioral symptoms including but not limited to anxiety, agitation, depression, irritability, apathy, or disinhibition * Able to undergo MRI scanning * Adequate auditory and visual abilities to complete study procedures as determined by the investigator. * Availability of a study partner (legally authorized representative, caregiver, or family member) who has regular contact with the participant and can provide collateral information and assist with assessments. * Ability to provide informed consent, or assent with legally authorized representative (LAR) consent in accordance with WVU IRB policy and applicable West Virginia law. .Currently under the care of a licensed physician, psychiatrist, or neurologist, and agrees to allow communication between investigators/study staff and healthcare providers for purposes of eligibility confirmation and safety monitoring. EXCLUSION CRITERIA * Moderate to severe dementia (i.e., beyond mild stage). * Clinically significant MRI abnormality that may jeopardize participant safety, study conduct, or confound diagnostic assessments. * History of clinically significant neurological disorder other than the qualifying dementia diagnosis that could confound evaluation or increase risk. * Major psychiatric disorder that would interfere with participation or safety, including psychosis, active suicidal ideation, or severe mood/anxiety disorder requiring immediate intervention. * Elevated suicide risk with History of medically verified suicide attempt within the past year. * Use of medications that significantly lower the seizure threshold or interfere with neuromodulation safety, as determined by the study physician. * Use of investigational drugs or participation in another interventional clinical trial within 30 days prior to screening. * Any condition that, in the opinion of the investigator, would interfere with study participation, safety, or interpretation of results.